{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-23-000119","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.958762+00:00","generated_at":"2026-06-12T02:20:28.637111+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Denali Q2 net income $183M on Biogen opt-in; discontinues DNL919 in Alzheimer's","bullets":["Net income $183.4M (Q2 2022: net loss $58.8M) on $294.1M collaboration revenue from Biogen's ATV:Abeta option.","Discontinued DNL919 (ATV:TREM2) in Alzheimer's due to narrow therapeutic window and evolving treatment landscape.","Biogen exercised option to license ATV-amyloid-beta program; will handle development and commercialization.","Revised BIIB122 (LRRK2) program: focus on LUMA study in Parkinson's; LIGHTHOUSE discontinued, no safety issues.","Cash and marketable securities $1.19B; DNL310 showed ~40-64% NfL reduction in MPS II, IND cleared for DNL126."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-23-000119","json":"https://secwatch.observer/filing/0001714899-23-000119.json","markdown":"https://secwatch.observer/filing/0001714899-23-000119.md","text":"https://secwatch.observer/filing/0001714899-23-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000119/0001714899-23-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000119/dnli-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:20:28.637111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81125eefc0d5e0f627d743350f682981ebadc4dc","claim":"Denali Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Denali Therapeutics Inc. (the \"Company\") issued a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000119/0001714899-23-000119-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}